220 related articles for article (PubMed ID: 36915460)
1. Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
Wan Y; Luo D
J Gastrointest Oncol; 2023 Feb; 14(1):450-457. PubMed ID: 36915460
[TBL] [Abstract][Full Text] [Related]
2. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of gemcitabine plus raltitrexed or S-1 versus standard third-line therapies in metastatic colorectal cancer: a retrospective cohort study.
Tao J; Zhang Y; Wang Y; Huang S; Gao W; Dai L; Feng Z; Jiao C; Zhang Y
J Gastrointest Oncol; 2024 Apr; 15(2):630-640. PubMed ID: 38756629
[TBL] [Abstract][Full Text] [Related]
4. Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study.
Li L; Wang T; Wu Z; Li Y; Ma H; Wang L; Lei S; Chen W
Transl Cancer Res; 2023 Nov; 12(11):3034-3044. PubMed ID: 38130300
[TBL] [Abstract][Full Text] [Related]
5. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
[TBL] [Abstract][Full Text] [Related]
7. Fruquintinib for refractory colorectal cancer in a pre-treated 82-year-old patient achieved a progression-free survival of 25 months: a case report.
Wang Y; Li J; Xu Q; Li K; Zhang C; Chen P
J Gastrointest Oncol; 2022 Oct; 13(5):2667-2671. PubMed ID: 36388671
[TBL] [Abstract][Full Text] [Related]
8. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
Dasari A; Sobrero A; Yao J; Yoshino T; Schelman W; Yang Z; Chien C; Kania M; Tabernero J; Eng C
Future Oncol; 2021 Aug; 17(24):3151-3162. PubMed ID: 33993740
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.
Chen Y; Zhou YW; Cheng K; Li ZP; Luo DY; Qiu M; Li Q; Wang X; Shen YL; Cao D; Yang Y; Bi F; Liu JY; Gou HF
Oncologist; 2021 Aug; 26(8):e1320-e1326. PubMed ID: 33830591
[TBL] [Abstract][Full Text] [Related]
10. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
Zhang Y; Zou JY; Wang Z; Wang Y
Cancer Manag Res; 2019; 11():7787-7803. PubMed ID: 31496821
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.
Dai Y; Sun L; Zhuang L; Zhang M; Zou Y; Yuan X; Qiu H
J Gastrointest Oncol; 2022 Apr; 13(2):722-731. PubMed ID: 35557597
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review.
Xu X; Yu Y; Liu M; Liang L; Liu T
Transl Cancer Res; 2022 Jan; 11(1):276-287. PubMed ID: 35261903
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer.
Zou J; Wang Y; Xu J; Li J; Wang T; Zhang Y; Bai Y
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202064
[TBL] [Abstract][Full Text] [Related]
14. Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review.
Li Y; Chen X; Li W; Ye Y; Du X; Sun S; Liu L; Zhang H
Front Oncol; 2021; 11():684309. PubMed ID: 34109130
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review.
Wu Y; Fan Y; Dong D; Dong X; Hu Y; Shi Y; Jing J; Li E
Ther Adv Med Oncol; 2020; 12():1758835920940932. PubMed ID: 32728393
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.
Gao L; Tang L; Hu Z; Peng J; Li X; Liu B
Front Oncol; 2023; 13():1269203. PubMed ID: 37810981
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
[TBL] [Abstract][Full Text] [Related]
18. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
Front Oncol; 2020; 10():587692. PubMed ID: 33282739
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer.
Matsuhashi N; Takahashi T; Fujii H; Suetsugu T; Fukada M; Iwata Y; Tokumaru Y; Imai T; Mori R; Tanahashi T; Matsui S; Imai H; Tanaka Y; Yamaguchi K; Futamura M; Yoshida K
Mol Clin Oncol; 2019 Oct; 11(4):390-396. PubMed ID: 31475067
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of raltitrexed plus S-1
Zhou YW; Wang JL; Li QF; He YL; Li LJ; Liu RZ; Chen Y; Zhang S; Qiu M; Liu JY
Therap Adv Gastroenterol; 2022; 15():17562848221098246. PubMed ID: 35601804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
